VDRM Breakout imminent!.
======================================
VDRM- "Debt Free & extremely profitable company!"
================================================
Can you find a small cap or any cap co with 0 Debt and totaly on its own, trading in the OTC!?...quite rare!.
1. Totally Debt free
2. 100% self owned, no notes or bonds or debt to anybody or any co
3. 1000% or multiples of it upto 5000% sales
4. 1000-5000% Growth
5. Cash position, self funded projects and future projects
6. No borrowing
7. Incredible organic, health products, clinical pipelines
8. Also part of CBD, hottest products on the planet
9. wound healing at its best
10.New M&A...
and more!
You just can't beat such a pristine OTC stocks, at less 3cents!?...it is laughable we can by shares just at 3c!?.
- Revenues from online retail sales for Q1 are estimated to be more than $23,000, representing an increase of 978% over the Q1, 2020 total and more than double the Company's total revenues for all of last year.
-- Proceeds of $90,000 from a previously announced licensing agreement have accounted for the majority of this year's Q1 revenues compared to 2020 when online retail sales accounted for 100% of all revenues.
-- The Company paid off all outstanding toxic convertible debt and is now completely debt free. Additionally, ViaDerma expects to self-fund all operations from this point and does not expect to take on any future debt.
-- At the request of ViaDerma, OTC Markets conducted a manual review of the Company's "shell risk" status and as a result has removed the "shell risk" annotation from ViaDerma's profile.
-- ViaDerma intends to submit an application this year for listing to the OTCQB. To qualify for OTCQB listing the Company needs to have one-year audited financials and add two independent directors.
